Disc Medicine Inc Dossier
Qualitative Analysis
Business overview
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapeutic candidates for serious hematologic diseases. The company's portfolio targets fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. Its key clinical-stage assets include bitopertin, an oral GlyT1 inhibitor being developed for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP); DISC-0974, a monoclonal antibody targeting hemojuvelin (HJV) for anemia of chronic disease and myelofibrosis; and DISC-3405, an anti-TMPRSS6 monoclonal antibody designed to induce hepcidin production for polycythemia vera (PV) and sickle cell disease (SCD).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead candidate bitopertin through the Phase 3 APOLLO trial to address the FDA's Complete Response Letter (CRL) and preparing commercial infrastructure (marketing, sales, and medical science liaisons) for a potential US launch.
Expected impact: Establishment of the first disease-modifying treatment for erythropoietic protoporphyria (EPP) and transition to a commercial-stage biopharmaceutical company.
Developing DISC-0974, a monoclonal antibody targeting hemojuvelin (HJV) to suppress hepcidin, for patients with anemia of myelofibrosis (MF) and expanding clinical development into other anemias of inflammation, including inflammatory bowel disease (IBD).
Expected impact: Validation of hepcidin suppression as a therapeutic mechanism to treat severe chronic anemias.
Advancing DISC-3405, an anti-TMPRSS6 monoclonal antibody designed to restrict iron availability, through Phase 2 proof-of-concept studies in polycythemia vera (PV) and Phase 1b studies in sickle cell disease (SCD).
Expected impact: Demonstration of therapeutic iron restriction as a novel treatment modality for hematologic diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Gemini Therapeutics via a reverse merger transaction to secure a public listing on the Nasdaq Global Market under the ticker symbol IRON and to obtain Gemini's remaining cash reserves to fund Disc's hematology pipeline.
Financial impact: Provided approximately $92 million in cash from Gemini's balance sheet, which, combined with concurrent financing, extended Disc's cash runway.
Strategic Partnerships
High; granted Disc Medicine exclusive global rights to develop and commercialize bitopertin, which is now the company's lead clinical candidate.
Terms: Exclusive worldwide license signed in May 2021.
High; granted Disc Medicine exclusive rights to develop and commercialize DISC-0974 and DISC-0998 (anti-HJV monoclonal antibodies) globally.
Terms: Exclusive license signed in September 2019.
High; granted Disc Medicine exclusive rights to develop and commercialize DISC-3405 in all territories outside of Greater China and Southeast Asia.
Terms: Exclusive license agreement to advance the anti-TMPRSS6 program.